aTyr Pharma presents preclinical data on ATYR2810 at AACR

aTyr Pharma (ATYR) announced that the Company will present a poster featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2, at the American Association for Cancer Research, AACR, Annual Meeting 2025, which is being held April 25 – 30, 2025, in Chicago, IL. “Aggressive cancers like glioblastoma multiforme continue to show drug resistance, and the efficacy of current immunotherapies may be limited due to immunosuppressive myeloid cells in the tumor microenvironment that contribute to drug resistance. We are pleased to see that ATYR2810 appears to combat drug resistance mechanisms, and we are particularly encouraged by its ability to increase survival and improve the effectiveness of checkpoint inhibitors in a GBM model,” said Leslie A. Nangle, Ph.D., Vice President, Research, at aTyr. “These findings, which were generated as part of our ongoing research collaboration with Dr. Michael Lim and Stanford Medicine, demonstrate the role of NRP2 in maintaining the immunosuppressive tumor microenvironment and suggest that blocking NRP2 may offer a new approach to treating GBM, both as a monotherapy and in combination with anti-PD-1 therapies.”